Pay in 4 interest-free payments of $5.84 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Serious Side Effects Rare but serious side effects include pancreatitis, gallbladder problems, kidney issues (usually from dehydration), and thyroid concerns
Indication for SOLIQUA 100/33 SOLIQUA 100/33 (insulin glargine and lixisenatide) is a combination of insulin glargine, an insulin analog, and lixisenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Potential Long-Term Risks of GLP-1s There are also potential long-term risks associated with the use of GLP-1, although further research is needed to understand these effects fully
Moreover, the platform is designed to handle a wide range of inquiries, from minor ailments to more complex health issues, ensuring that patients feel supported throughout their healthcare journey
